康美药业
(600518)
| 流通市值：326.71亿 | | | 总市值：332.73亿 |
| 流通股本：136.13亿 | | | 总股本：138.64亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,873,558,308.67 | 2,474,338,981.11 | 1,201,239,538.91 | 4,874,016,143.02 |
| 营业收入 | 3,873,558,308.67 | 2,474,338,981.11 | 1,201,239,538.91 | 4,874,016,143.02 |
| 二、营业总成本 | 4,077,729,703.82 | 2,594,554,526.67 | 1,270,757,840.22 | 4,894,618,384.06 |
| 营业成本 | 3,325,075,721.52 | 2,114,136,624.51 | 1,027,901,413.52 | 4,042,159,412.35 |
| 税金及附加 | 34,368,660.08 | 22,255,942.78 | 11,188,356.36 | -274,182,215.34 |
| 销售费用 | 312,989,742.49 | 191,811,754.35 | 95,758,231.06 | 551,782,111.34 |
| 管理费用 | 376,004,973.56 | 244,839,095.94 | 126,369,869.63 | 502,122,894.27 |
| 研发费用 | 32,164,804.25 | 22,786,036.19 | 10,361,546.22 | 45,617,688.46 |
| 财务费用 | -2,874,198.08 | -1,274,927.1 | -821,576.57 | 27,118,492.98 |
| 其中:利息费用 | 8,550,479.25 | 6,090,680.42 | 2,985,213.68 | 56,154,221.88 |
| 其中:利息收入 | 12,151,440.71 | 7,844,072.99 | 4,030,736.82 | 30,743,722.44 |
| 加:公允价值变动收益 | -395.39 | -10,042.73 | -5,258.59 | -34,507.04 |
| 加:投资收益 | 63,646,590.12 | 41,797,752.78 | 29,527,342.86 | 44,433,689.78 |
| 资产处置收益 | 28,206,492.87 | 28,362,807.9 | 26,126,966.15 | 19,607,384.25 |
| 资产减值损失(新) | -465,843.53 | -467,400.14 | 1,590.46 | -197,551,563.65 |
| 信用减值损失(新) | 55,987,468.51 | 48,907,117.2 | 13,576,010.75 | 202,165,029.42 |
| 其他收益 | 16,007,671.49 | 19,781,209.49 | 9,880,782.38 | 38,648,480.38 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -40,789,411.08 | 18,155,898.94 | 9,589,132.7 | 86,666,272.1 |
| 加:营业外收入 | 66,408,066.67 | 9,095,908.95 | 583,498.86 | 57,882,283.63 |
| 减:营业外支出 | 6,523,211.95 | 2,434,508.07 | 508,099.58 | 34,181,945.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 19,095,443.64 | 24,817,299.82 | 9,664,531.98 | 110,366,610.08 |
| 减:所得税费用 | 10,984,567.53 | 6,697,106.52 | 1,051,715.27 | 6,799,677.97 |
| 六、净利润 | 8,110,876.11 | 18,120,193.3 | 8,612,816.71 | 103,566,932.11 |
| 持续经营净利润 | 8,110,876.11 | 18,120,193.3 | 8,612,816.71 | 103,566,932.11 |
| 归属于母公司股东的净利润 | 5,015,537.6 | 15,760,325.84 | 7,471,308.45 | 102,521,231.11 |
| 少数股东损益 | 3,095,338.51 | 2,359,867.46 | 1,141,508.26 | 1,045,701 |
| (一)基本每股收益 | 0 | 0 | 0 | 0.01 |
| (二)稀释每股收益 | 0 | 0 | 0 | 0.01 |
| 八、其他综合收益 | -118,139.61 | -151,916.83 | -21,772.56 | -235,819.61 |
| 归属于母公司股东的其他综合收益 | -118,139.61 | -151,916.83 | -21,772.56 | -235,819.61 |
| 九、综合收益总额 | 7,992,736.5 | 17,968,276.47 | 8,591,044.15 | 103,331,112.5 |
| 归属于母公司股东的综合收益总额 | 4,897,397.99 | 15,608,409.01 | 7,449,535.89 | 102,285,411.5 |
| 归属于少数股东的综合收益总额 | 3,095,338.51 | 2,359,867.46 | 1,141,508.26 | 1,045,701 |
| 公告日期 | 2024-10-31 | 2024-08-24 | 2024-04-30 | 2024-04-13 |
| 审计意见(境内) | | | | 标准无保留意见 |